Abstract
To assess whether non-K1, group 2 capsular serotypes are important in conferring serum resistance to extraintestinal isolates of Escherichia coli, a K54 blood isolate (CP9) was evaluated as a model pathogen. Transposon mutagenesis (TnphoA) was used to generate isogenic capsule-negative mutants. CP9 was resistant to the bactericidal effects of serum, growing in 80% serum. In contrast, all of the capsule-negative mutants had an increased sensitivity to 80% normal human serum, undergoing a 2- to 3-log kill over 3 h when starting inocula of 104 to 107 CFU/ml were used. The killing of the capsule-negative strains was mediated through the alternative complement pathway and not by lysozyme or beta-lysins. The protective effect of the K54 capsule against the bactericidal activity of serum was not through inhibition of the complement cascade, nor did it appear to be through a difference in the binding of C3.
| Original language | English |
|---|---|
| Pages (from-to) | 3578-3582 |
| Number of pages | 5 |
| Journal | Infection and Immunity |
| Volume | 61 |
| Issue number | 8 |
| State | Published - 1993 |
Fingerprint
Dive into the research topics of 'TnphoA-mediated disruption of K54 capsular polysaccharide genes in Escherichia coli confers serum sensitivity'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver